CTKB

Cytek is a flow-cytometry instrument maker (Full Spectrum Profiling analyzers plus the acquired Amnis/Guava lines) whose growth engine has stalled: FY2025 revenue of $201M was up just 0.5%, the tail end of a sharp deceleration from the $128M→$164M→$193M→$200M ramp of prior years. The MD&A itself frames 2025 as a '1% increase,' and the mix is quietly worsening — distributor revenue rose to 27% of sales from 24% two years ago, a lower-touch, lower-margin channel. Gross profit actually fell 6.0% to $104M and gross margin compressed to 51.8%, so the business sold no more product and kept less of each dollar. Most telling for a company whose entire thesis is 'continued innovation,' R&D was cut for a second straight year ($44.2M→$39.4M→$36.5M). Trimming R&D while revenue flatlines is a defensive, not offensive, posture.

Profitability deteriorated dramatically: operating income swung to -$40.4M (-20% margin) and net income collapsed to -$66.5M from -$6.02M. Note the ~$26M gap between the operating and net loss points to a sizeable non-operating/below-the-line charge, so the -$66.5M headline overstates the cash-operating run-rate — the -$40.4M operating loss and the -$4.69M operating cash outflow are the truer measure of the burn. Retained earnings have gone deeply negative (-$102M) and ROE is -19.5%.